Related Experiment Video
Updated: May 20, 2025
Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
Exploring shared therapeutic targets for Alzheimer's disease and glioblastoma using network pharmacology and
Sushma Pradeep1,2, M R Sai Chakith3, S R Sindhushree1
1Department of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.
Background:
Alzheimer's disease (AD) and glioblastoma (GBM) are complex neurological disorders with distinct pathologies but overlapping molecular mechanisms, including neuroinflammation, oxidative stress, and dysregulated signaling pathways. Despite significant advancements in research, effective therapies targeting both conditions remain elusive. Identifying shared molecular targets and potential therapeutic agents could offer novel treatment strategies for these disorders.
Methodology:
The study employs an integrative network pharmacology approach to explore the therapeutic potential of bioactive compounds from Eclipta alba, a medicinal herb known for its neuroprotective and anti-inflammatory properties. A systematic methodology was adopted, starting with network pharmacology analysis using STRING and DisGeNET databases, which identified 617 common genes associated with AD and GBM. Among these, key hub genes-TP53, STAT3, AKT1, and IL6-were prioritized using Cytoscape for network visualization and analysis.
Results:
Molecular docking studies were conducted using PyRx software to assess the binding interactions of 26 phytochemicals from Eclipta alba against the identified target genes. Luteolin exhibited the highest binding affinity to IL6 (-7.8 kcal/mol), forming stable hydrogen bonds and hydrophobic interactions. To further validate this interaction, molecular dynamics simulations (MDS) were performed using GROMACS, confirming the stability of the Luteolin-IL6 complex. Additionally, MM-PBSA binding energy calculations using AmberTools (-145.44 kJ/mol) provided further evidence of a strong and stable interaction. Pharmacokinetic and toxicity evaluations, conducted using SwissADME and pkCSM, highlighted luteolin's favorable drug-like properties, including good bioavailability and low toxicity. These findings suggest that luteolin may serve as a promising multi-target therapeutic agent for AD and GBM by modulating key pathological pathways.
Conclusion:
The present study provides a strong computational foundation for further in vitro and in vivo validation. The results highlight the potential of luteolin in developing dual-target treatment strategies for neurodegenerative and oncological disorders, offering new avenues for therapeutic advancements.
Insights
This study explored Eclipta alba compounds for Alzheimer's disease (AD) and glioblastoma (GBM). Luteolin showed promise as a dual-target therapeutic agent by effectively binding to key genes involved in both neurological disorders.
Area of Science:
- Neuroscience
- Pharmacology
- Computational Biology
Background:
- Alzheimer's disease (AD) and glioblastoma (GBM) share molecular mechanisms like neuroinflammation and oxidative stress.
- Current therapies for AD and GBM are limited, necessitating novel treatment strategies.
- Identifying shared molecular targets is crucial for developing effective dual-action treatments.
Purpose of the Study:
- To investigate the therapeutic potential of bioactive compounds from *Eclipta alba* for AD and GBM.
- To identify common molecular targets and potential drug candidates using network pharmacology.
- To evaluate the efficacy and safety of promising compounds through computational methods.
Main Methods:
- Network pharmacology analysis identified 617 common genes between AD and GBM.
- Key hub genes (TP53, STAT3, AKT1, IL6) were prioritized using Cytoscape.
- Molecular docking, dynamics simulations, and pharmacokinetic/toxicity assessments were performed.
Main Results:
- Luteolin from *Eclipta alba* demonstrated high binding affinity to the IL6 target.
- Molecular dynamics and binding energy calculations confirmed the stability of the luteolin-IL6 complex.
- Luteolin exhibited favorable pharmacokinetic properties and low toxicity, suggesting therapeutic potential.
Conclusions:
- Luteolin is a promising multi-target therapeutic agent for AD and GBM.
- Computational findings provide a basis for future *in vitro* and *in vivo* validation.
- This research opens new avenues for developing dual-target treatments for neurological and oncological disorders.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
11:49Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue
Published on: August 28, 2021
Related Concept Videos
02:26Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
02:04Protein-protein Interfaces
01:22Alzheimer's Disease: Treatment
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:00Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...